BioSpace News Archive

Fractures due to osteoporosis, a skeletal disorder characterized by low bone mineral density1, have been labelled a public health crisis.2 This is in part due to an increasing number of older adults at risk of fractures due to osteoporosis as well as the low rates of osteoporosis management in patients who experience a fragility fracture across Europe and North America.3

Bio-Techne Corporation announced that Chuck Kummeth, President and Chief Executive Officer, will present at the Barclays Global Healthcare Conference on Thursday, March 11, 2021 at 9:10 a.m. EST.

Strata Oncology, Inc., a precision oncology company advancing molecular indications for cancer therapies, announced the Strata Precision Indications for Approved Therapies, or “Strata PATH,” trial.

Gala Therapeutics, Inc., a developer of medical devices to treat chronic bronchitis and other pulmonary diseases, announced that it has appointed Douglas Godshall to chair of its Board of Directors.

MONTREAL, March 2, 2021 /PRNewswire/ - Ortho Regenerative Technologies Inc., a clinical stage orthobiologics company focused on the development of novel soft tissue repair regenerative technologies, provided a review of 2020 calendar year activities and a look forward at planned future milestones as the Company transitions from preclinical to clinical stage.

PYC Therapeutics (ASX: PYC), a biotechnology company developing a new generation of precision RNA therapeutics to change the lives of patients with inherited diseases, today announced that the Company’s lead investigational drug, VP-001, for the treatment of RP11 has restored function of the Retinal Pigment Epithelium

Agreement focused on advancing Mitokinin’s PINK1 activator program for the potential treatment of Parkinson’s disease

Science 37, the industry leader in decentralized clinical trials, announced a strategic partnership with Medgate, a leading international digital health and telemedicine company and operator of Europe’s largest telemedicine center run by physicians.

Transgene, a biotech company that designs and develops virus-based immunotherapeutics against cancer, announces that members of Transgene’s management and scientific team have been invited to participate at upcoming scientific conferences:

Certification is deemed an international seal of approval and guarantees the highest quality standards for pharmaceutical excipients and other critical materials used by the pharmaceutical industry, such as DENARASE, a c-LEcta enzyme product that is used in the production of biopharmaceuticals and vaccines